Patent · US Active

Method for the treatment of cardiovascular fibrosis

US9594083B2 · kind B2 · utility

1Cited by

0References

1Claims

0Family size

Assignees

INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
Universite de Lorraine · FR
Cantre Hospitalier et Universitaire de Nancy (CHU) · FR
UNIVERSITÉ PARIS DIDEROT—PARIS 7 · FR
UNIVERSITE DE PARIS DESCARTES · FR

Inventors

Frederic Jaisser · Paris, FR
Nicolette Farman · Paris, FR
Antoine Tarjus · Paris, FR
Patrick Rossignol · Vandœuvre-lès-Nancy, FR
Faiez Zannad · Vandœuvre-lès-Nancy, FR

Key dates

Filing date	Sep 27, 2013
Grant date	Mar 14, 2017
Priority date	—
Expiry date	Sep 27, 2033

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/325
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of cardiovascular fibrosis. In particular, the present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing cardiovascular fibrosis in a subject in need thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.